NCT01594216 2024-06-12
Ruxolitinib in Estrogen Receptor Positive Breast Cancer
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
Clinical Trials
4 trialsNCT03012230 2024-01-31
Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer
Mayo Clinic
Phase 1 Completed
NCT02066532 2023-08-24
Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer
Columbia University
Phase 1/2 Completed
NCT02041429 2021-04-21
Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca
Dana-Farber Cancer Institute
Phase 1/2 Completed